Pegadricase

Summary

Pegadricase (CHEMBL2108722) is a phase-3 clinical-stage enzyme; indicated across 1 condition including gout.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108722
Name	Pegadricase
Type	Enzyme
Max phase	3

Also known as: Pegadricasa, Pegadricase, Pegadricase component of sel-212, Pegsiticase, Sel-037, SEL-037, URICASE-PEG 20, URICASE-PEG-20, URICASE-PEG20, PEGADRICASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gout	3	MONDO:0005393	EFO:0004274

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02959918	PHASE2	COMPLETED	Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
NCT01021241	PHASE1	UNKNOWN	Safety and Efficacy Study of Intravenous Uricase-PEG 20
NCT01038947	PHASE1	UNKNOWN	Safety and Efficacy Study of Intramuscular Uricase-PEG 20
NCT02464605	PHASE1	COMPLETED	Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
NCT02648269	PHASE1	COMPLETED	Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).